跳至主要内容
临床试验/IRCT20140818018842N22
IRCT20140818018842N22招募中2 期

Evaluation of safety and immunogenicity of the SARS-CoV-2 recombinant spike RBD protein vaccine in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation; A phase 2 clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • Allogeneic stem cell transplantation
  • successfully engraftment with full donor chimerism
  • between 3 to 12 months after Allo-HSCT

排除标准

  • grade 3,4 acute GvHD or severe extensive chronic GvHD
  • Patients who do not consent to vaccination after transplantation
  • receive more than 0.5 mg/kg/day prednisolone
  • positive RT-PCR test for COVID-19 during the last three months

研究者

相似试验

Evaluation of the COVID-19 vaccine efficacy... | 临床试验